A Phase 3 interventional study of Pamrevlumab and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by FibroGen. Terminated at 125 sites in 9 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by FibroGen · Phase 3, Interventional, and Treatment
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 23rd largest by enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2019, is one of 37 in phase 3, and was the 138th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Oorja Bio, Inc. · Sites in United States
Ages 40+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 11 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 393 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 85 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
Kyntra Bio has 5 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to evaluate the efficacy and safety of pamrevlumab in participants with IPF.
Participants who are not being treated with approved IPF therapies (that is, nintedanib or pirfenidone) may be eligible for screening. Examples of reasons participants may not be treated with approved IPF therapies include but are not limited to:
NOTE: No participant should discontinue an approved IPF therapy for the purpose of enrolling in this study.
The study consists of the following study periods:
Main (double blind, placebo-controlled) phase:
Optional, open-label extension (OLE) phase of pamrevlumab:
o Access to pamrevlumab will be available until the last participant completes 48 weeks of treatment in the OLE phase, or pamrevlumab is commercially available for the indication of IPF, or the Sponsor decides to end the OLE phase, whichever occurs first.
Follow-up period/final safety assessments:
During the treatment period, co-administration of an approved IPF therapy (that is, pirfenidone or nintedanib) is acceptable if clinically indicated in the Investigator's opinion, provided that the Investigator assesses the potential risks/benefits of combining approved IPF therapies with blinded study treatment.
Participants who discontinue study treatment for any reason should be encouraged to remain in the study and be followed for all study visits and assessments.
Participants who complete the Week 48 visit of the main study (regardless of the number of study drug infusions received) will be eligible to participate in the optional OLE phase of the study that offers continuing access to pamrevlumab regardless of randomization assignment in the main study.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pamrevlumab 30 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 3 weeks for up to 48 weeks in the DB period.
Drug: Pamrevlumab
Participants will receive placebo matching to pamrevlumab by IV infusion every 3 weeks for up to 48 weeks in the DB period.
Drug: Placebo
Participants will receive pamrevlumab 30 mg/kg by IV infusion every 3 weeks for up to 48 weeks.
Drug: Pamrevlumab
Participants will receive placebo matching to pamrevlumab by IV infusion every 3 weeks for up to 48 weeks.
Drug: Placebo
Participants who receive pamrevlumab in the DB period will continue to receive the same dose of pamrevlumab for up to 48 weeks in the OLE period or until pamrevlumab is commercially available for the indication of IPF, or the sponsor decides to end the OLE period, whichever occurrs first.
Drug: Pamrevlumab
Participants who receive placebo matching to pamrevlumab in the DB period, will receive pamrevlumab 30 mg/kg by IV infusion every 3 weeks for up to 48 weeks in the OLE period or until pamrevlumab is commercially available for the indication of IPF, or the sponsor decides to end the OLE period, whichever occurrs first.
Drug: Pamrevlumab
Pamrevlumab will be administered per dose and schedule specified in the arm description.
Also known as: FG-3019
Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
DB Period (Main Study Cohort): Change From Baseline in FVC at Week 48
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that could forcibly be blown out after full inspiration in the upright position, measured in liters. Least square (LS) mean and standard error (SE) were calculated using mixed model for repeated measures (MMRM).
Time frame: Baseline, Week 48
DB Period (Japan Extension Cohort): Change From Baseline in FVC at Week 48
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that could forcibly be blown out after full inspiration in the upright position, measured in liters.
Time frame: Baseline, Week 48
DB Period (Main Study Cohort): Time to Disease Progression
Time to disease progression was defined as the number of weeks from randomization to either the first occurrence of an absolute ≥10% decline from baseline in percent predicted FVC (FVCpp) or all-cause death, whichever occurred first. Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
Time frame: Up to Week 48
DB Period (Main Study Cohort): Time to First Occurrence of Any Component of the Clinical Composite Endpoint
The components of the clinical composite endpoint included acute IPF exacerbation, respiratory hospitalization, or death. Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
Time frame: Up to Week 48
DB Period (Main Study Cohort and Japan Extension Cohort): Change From Baseline in Quantitative Lung Fibrosis (QLF) Volume at Week 48
The QLF volume was calculated as QLF = total lung capacity volume multiplied by percentage (%) of quantitative lung fibrosis for fibrosis of the whole lung. LS mean and SE was calculated using MMRM.
Time frame: Baseline, Week 48
DB Period (Main Study Cohort): Time to First Acute IPF Exacerbation
Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
Time frame: Up to Week 48
DB Period (Main Study Cohort): Time to All-Cause Mortality
Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
Time frame: Up to Week 48
DB Period (Main Study Cohort): Time to First Respiratory Hospitalizations
Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
Time frame: Up to Week 48
| Milestone | Main Study Cohort: Pamrevlumab | Main Study Cohort: Placebo | Japan Extension Cohort: Pamrevlumab | Japan Extension Cohort: Placebo |
|---|---|---|---|---|
| Started | 181 | 175 | 18 | 19 |
| Received at least 1 dose of study drug | 181 | 175 | 18 | 19 |
| Completed | 146 | 134 | 14 | 11 |
| Not completed | 35 | 41 | 4 | 8 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 4 |
| Withdrew: Adverse event | 2 | 5 | 1 | 2 |
| Withdrew: Death | 13 | 17 | 1 | 0 |
| Withdrew: Investigator decision | 2 | 2 | 0 | 0 |
| Withdrew: Disease progression | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 0 | 1 |
| Withdrew: Noncompliance with the study drug | 1 | 1 | 0 | 0 |
| Withdrew: Lung transplant | 0 | 1 | 0 | 0 |
| Withdrew: Participant decision | 9 | 12 | 1 | 1 |
| Milestone | Main Study Cohort: Pamrevlumab | Main Study Cohort: Placebo | Japan Extension Cohort: Pamrevlumab | Japan Extension Cohort: Placebo |
|---|---|---|---|---|
| Started | 129 | 123 | 0 | 0 |
| Received at least 1 dose of study drug | 129 | 123 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 129 | 123 | 0 | 0 |
| Withdrew: Adverse event | 7 | 1 | 0 | 0 |
| Withdrew: Death | 12 | 12 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Investigator decision | 2 | 2 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 84 | 88 | 0 | 0 |
| Withdrew: Disease progression | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 0 | 0 |
| Withdrew: Lung transplant | 2 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Participant decision | 12 | 13 | 0 | 0 |
| Withdrew: Other than specified | 1 | 0 | 0 | 0 |
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that could forcibly be blown out after full inspiration in the upright position, measured in liters. Least square (LS) mean and standard error (SE) were calculated using mixed model for repeated measures (MMRM).
| liters | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo |
|---|---|---|
| DB Period (Main Study Cohort): Change From Baseline in FVC at Week 48 | -0.26 ± 0.046 | -0.33 ± 0.050 |
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that could forcibly be blown out after full inspiration in the upright position, measured in liters.
| liters | DB Period (Japan Extension Cohort) - Pamrevlumab | DB Period (Japan Extension Cohort) - Placebo |
|---|---|---|
| DB Period (Japan Extension Cohort): Change From Baseline in FVC at Week 48 | -0.0445 ± 0.1805 | -0.1835 ± 0.2389 |
Time to disease progression was defined as the number of weeks from randomization to either the first occurrence of an absolute ≥10% decline from baseline in percent predicted FVC (FVCpp) or all-cause death, whichever occurred first. Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
| weeks | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo |
|---|---|---|
| DB Period (Main Study Cohort): Time to Disease Progression | 54.3 (52.7 to NA) | 50.7 (50.3 to 54.0) |
The components of the clinical composite endpoint included acute IPF exacerbation, respiratory hospitalization, or death. Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
| weeks | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo |
|---|---|---|
| DB Period (Main Study Cohort): Time to First Occurrence of Any Component of the Clinical Composite Endpoint | 62.7 (59.0 to NA) | NA (57.9 to NA) |
The QLF volume was calculated as QLF = total lung capacity volume multiplied by percentage (%) of quantitative lung fibrosis for fibrosis of the whole lung. LS mean and SE was calculated using MMRM.
| liters | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo | DB Period (Japan Extension Cohort): Pamrevlumab | DB Period (Japan Extension Cohort): Placebo |
|---|---|---|---|---|
| DB Period (Main Study Cohort and Japan Extension Cohort): Change From Baseline in Quantitative Lung Fibrosis (QLF) Volume at Week 48 | 251.38 ± 38.010 | 267.96 ± 38.763 | 45.08 ± 88.265 | 78.18 ± 119.300 |
Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
| weeks | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo |
|---|---|---|
| DB Period (Main Study Cohort): Time to First Acute IPF Exacerbation | 62.7 (62.7 to NA) | NA (NA to NA) |
Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
| weeks | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo |
|---|---|---|
| DB Period (Main Study Cohort): Time to All-Cause Mortality | NA (60.6 to NA) | NA (60.1 to NA) |
Median Time to Event' is an estimated value, which was calculated based on Kaplan-Meier method. Hence, the 'Median Time to Event' is longer than the reported timeframe of 48 weeks.
| weeks | DB Period (Main Study Cohort) - Pamrevlumab | DB Period (Main Study Cohort) - Placebo |
|---|---|---|
| DB Period (Main Study Cohort): Time to First Respiratory Hospitalizations | 62.7 (59.0 to NA) | NA (57.9 to NA) |
Collected over From first dose of study drug until 60 days after last dose of study drug (maximum exposure: 51.1 weeks [in main study cohort DB period], 49.1 weeks [in Japan extension cohort DB period], and 153.1 weeks [in OLE period]. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period (Main Study Cohort): Pamrevlumab | 23/181 (12.7%) | 51/181 (28.2%) | 129/181 (71.3%) |
| DB Period (Main Study Cohort): Placebo | 22/175 (12.6%) | 60/175 (34.3%) | 121/175 (69.1%) |
| DB Period (Japan Extension Cohort)Pamrevlumab | 1/18 (5.6%) | 5/18 (27.8%) | 17/18 (94.4%) |
| DB Period (Japan Extension Cohort): Placebo | 2/19 (10.5%) | 8/19 (42.1%) | 16/19 (84.2%) |
| OLE Period: Pamrevlumab/Pamrevlumab | 17/129 (13.2%) | 42/129 (32.6%) | 76/129 (58.9%) |
| OLE Period: Placebo/Pamrevlumab | 14/123 (11.4%) | 33/123 (26.8%) | 75/123 (61%) |
| Event | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort)Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | OLE Period: Pamrevlumab/Pamrevlumab | OLE Period: Placebo/Pamrevlumab |
|---|---|---|---|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 14/181 | 18/175 | 2/18 | 3/19 | 16/129 | 14/123 |
| PneumoniaInfections and infestations | 8/181 | 8/175 | 1/18 | 1/19 | 5/129 | 4/123 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/181 | 0/175 | 1/18 | 0/19 | 0/129 | 0/123 |
| UrticariaSkin and subcutaneous tissue disorders | 0/181 | 0/175 | 1/18 | 0/19 | 0/129 | 0/123 |
| MelaenaGastrointestinal disorders | 0/181 | 0/175 | 0/18 | 1/19 | 0/129 | 0/123 |
| PyrexiaGeneral disorders | 0/181 | 0/175 | 0/18 | 1/19 | 0/129 | 1/123 |
| Cholecystitis acuteHepatobiliary disorders | 0/181 | 1/175 | 0/18 | 1/19 | 1/129 | 0/123 |
| COVID-19Infections and infestations | 3/181 | 1/175 | 0/18 | 1/19 | 2/129 | 0/123 |
| DiverticulitisInfections and infestations | 0/181 | 1/175 | 0/18 | 1/19 | 0/129 | 0/123 |
| Chemical peritonitisInjury, poisoning and procedural complications | 0/181 | 0/175 | 0/18 | 1/19 | 0/129 | 0/123 |
| Event | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort)Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | OLE Period: Pamrevlumab/Pamrevlumab | OLE Period: Placebo/Pamrevlumab |
|---|---|---|---|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 19/181 | 17/175 | 1/18 | 7/19 | 7/129 | 7/123 |
| COVID-19Infections and infestations | 22/181 | 16/175 | 5/18 | 2/19 | 14/129 | 11/123 |
| DiarrhoeaGastrointestinal disorders | 10/181 | 11/175 | 4/18 | 4/19 | 8/129 | 5/123 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/181 | 25/175 | 3/18 | 2/19 | 11/129 | 14/123 |
| NasopharyngitisInfections and infestations | 10/181 | 6/175 | 1/18 | 3/19 | 6/129 | 3/123 |
| BronchitisInfections and infestations | 14/181 | 14/175 | 0/18 | 0/19 | 15/129 | 9/123 |
| ProctalgiaGastrointestinal disorders | 0/181 | 0/175 | 2/18 | 0/19 | 0/129 | 0/123 |
| Infusion site erythemaGeneral disorders | 0/181 | 0/175 | 2/18 | 0/19 | 0/129 | 0/123 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/181 | 1/175 | 2/18 | 1/19 | 2/129 | 1/123 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 2/181 | 3/175 | 2/18 | 0/19 | 2/129 | 0/123 |
The intent-to-treat (ITT) population included all randomized participants.
| Age, Customized(Participants) | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort): Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | Total |
|---|---|---|---|---|---|
| ≤64 Years | 41 | 28 | 3 | 5 | 77 |
| 65 - 74 Years | 77 | 94 | 10 | 5 | 186 |
| ≥75 Years | 63 | 53 | 5 | 9 | 130 |
| Sex: Female, Male(Participants) | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort): Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | Total |
|---|---|---|---|---|---|
| Female | 49 | 49 | 5 | 3 | 106 |
| Male | 132 | 126 | 13 | 16 | 287 |
| Ethnicity (NIH/OMB)(Participants) | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort): Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 54 | 44 | 0 | 0 | 98 |
| Not Hispanic or Latino | 127 | 131 | 18 | 19 | 295 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort): Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 63 | 69 | 18 | 19 | 169 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 117 | 104 | 0 | 0 | 221 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Forced Vital Capacity (FVC)(liters) | DB Period (Main Study Cohort): Pamrevlumab | DB Period (Main Study Cohort): Placebo | DB Period (Japan Extension Cohort): Pamrevlumab | DB Period (Japan Extension Cohort): Placebo | Total |
|---|---|---|---|---|---|
| Main Study Cohort | 2.3668 ± 0.6185 | 2.4161 ± 0.6453 | — | — | 2.3911 ± 0.6314 |
| Japan Extension Cohort | — | — | 2.5864 ± 0.5521 | 2.5486 ± 0.5153 | 2.5670 ± 0.5264 |
Showing the first 100 of 125 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2019 to primary completion in Mar 2023, 45 months.
Results were first posted in Sep 2024, 1 year 5 months after primary completion. A results delay was requested in Mar 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pamrevlumab
Idiopathic Pulmonary Fibrosis →